Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells
Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio · 2026
Read Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells by Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13576371.txt.
Description
Lucy Bonilla and ten co-authors found two sibling immune proteins push pancreatic cancer cells in opposite directions in a 2026 paper. Pancreatic tumors resist the standard drug gemcitabine, partly by eating their own parts through autophagy. The team treated tumor cells with two type I interferons and tracked survival, self-eating markers, and signaling.
One interferon sped autophagy up and shielded cells from the drug. The other cut autophagosome formation and made the drug kill far better. Both switched on the expected signaling protein, so the split lies deeper in the pathway. The authors suggest the second interferon as a partner for chemotherapy, and warn the first may protect tumors.
Catalog record
| CREATOR | Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |